Drug intelligence / Profile preview

CR BNO 1055 + tamoxifen

Development stage
Unknown
Lead developer
Bionorica
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

CR BNO 1055 + tamoxifen is a combination of a standardized extract of Cimicifuga racemosa (black cohosh), known as CR BNO 1055, and the selective estrogen receptor modulator (SERM) tamoxifen. - **CR BNO 1055** is an ethanolic extract of black cohosh rhizome used primarily for menopausal symptoms such as hot flashes and night sweats. Its mechanism appears to involve modulation of serotonin receptors (notably 5-HT1A and 5-HT7), dopaminergic activity via D2 receptors, possible μ-opioid receptor affinity, and SERM-like effects in certain tissues without uterotrophic activity[1][6][7]. - **Tamoxifen** is a well-established SERM that acts as an estrogen receptor antagonist in breast tissue but can have agonist effects in other tissues. It is widely used for hormone receptor-positive breast cancer treatment and prevention. The rationale for combining these agents may be to manage menopausal symptoms or mitigate side effects associated with endocrine therapy in women with or at risk for breast cancer.

Brand names
KlimadynonMenofemRemifeminNolvadex
Other names
Cimicifuga racemosa extract + tamoxifenblack cohosh extract + tamoxifen
02

Targets

HTR7 (5-hydroxytryptamine receptor 7)DRD2 (Dopamine D2 Receptor)ER (Estrogen receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on CR BNO 1055 + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR BNO 1055 + tamoxifen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call